Granulocyte-colony Stimulating Factor for Stem Cells Therapy for Acute Ischemic Stroke (STEMTHER)
This study has been completed.
Sponsor:
Clinical Institute of the Brain, Russia
Collaborators:
Institute of Medical Cells Technologies
City Clinical Hospital #40
Information provided by:
Clinical Institute of the Brain, Russia
ClinicalTrials.gov Identifier:
NCT00901381
First received: May 12, 2009
Last updated: January 6, 2014
Last verified: January 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of the study is to investigate treatment with Leukostim (Filgrastim; granulocyte-colony stimulating factor; G-CSF) for acute ischemic stroke.
| Condition | Intervention | Phase |
|---|---|---|
|
Ischemic Stroke |
Drug: Filgrastim |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Open Prospective Randomized Controlled Trial of Efficacy and Safety of Granulocyte-colony Stimulating Factor Leukostim for Acute Ischemic Stroke. |
Resource links provided by NLM:
Further study details as provided by Clinical Institute of the Brain, Russia:
Primary Outcome Measures:
- Dependence assessed by the modified Rankin scale [ Time Frame: 180 day ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Impairment assessed by the Medical Research Consul scale and National Institutes of Health Stroke Scale [ Time Frame: 180 day ] [ Designated as safety issue: No ]
- Disability assessed by the Barthel Index and Glasgow Outcome Scale [ Time Frame: 180 day ] [ Designated as safety issue: No ]
- Infarct size assessed by the magneto-resonance imaging [ Time Frame: 180 day ] [ Designated as safety issue: No ]
- Safety was assessed as mortality, incidence of hemorrhagic transformation and serious adverse events [ Time Frame: Duration of study ] [ Designated as safety issue: Yes ]
| Enrollment: | 20 |
| Study Start Date: | June 2007 |
| Study Completion Date: | February 2009 |
| Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: G-CSF |
Drug: Filgrastim
10 µg/kg subcutaneously once daily x 5 days
Other Name: Leukostim
|
| No Intervention: Control |
Detailed Description:
Stroke is one of the main reasons of mortality and morbidity all over the world. In economically developed countries stroke takes 2 or 3 place in the structure of morbidity and mortality. In animal models, it was shown that autological stem cells transplantation significantly increased perfusion of ischemic area and improved lost motor and sensor functions. Granulocyte-colony stimulating factor (G-CSF) was used in some clinical trials without following autological transplantation. However, there are no enough evidence-based proved results of G-GSF safety and effectiveness in acute ischemic stroke. In order to determine safety and efficiency of G-CSF administration together with conventional treatment and conventional intensive care protocol during acute ischemic stroke we organized this clinical trial.
Eligibility| Ages Eligible for Study: | 40 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age between 40 to 70 years old
- CT/MRI confirmed ischemic stroke in carotid area during 48 hours after the onset of clinical signs
- Level of conscious lower than 15 and higher than 8 points by the Glasgow Coma Scale
- Acute extremity paresis lower than 4 points by Medical Research Consul scale
Exclusion Criteria:
- Premorbid dependency (modified Rankin Scale > 0)
- Intracerebral hemorrhage
- Transitory ischemic attack
- Patients with previous stroke
- Any disorders, that can affect interpretation of results (e.g. psychiatric or movement disorders)
- Hematological diseases
- Coagulopathy
- Malignancy
- Pregnancy and lactation
- Organ dysfunction that would preclude tests required for this study
- Known allergic reaction to G-CSF or a component of G-CSF
- Patients that have received a cytokine within the last 1 month or are currently receiving a cytokine treatment
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00901381
Please refer to this study by its ClinicalTrials.gov identifier: NCT00901381
Locations
| Russian Federation | |
| Clinical Institute of the Brain | |
| Ekaterinburg, Russian Federation, 620026 | |
Sponsors and Collaborators
Clinical Institute of the Brain, Russia
Institute of Medical Cells Technologies
City Clinical Hospital #40
Investigators
| Principal Investigator: | Andrey A Belkin, MD, PhD. | Clinical Institute of the Brain, Russia |
More Information
Additional Information:
No publications provided
| Responsible Party: | Andrey Belkin, Clinical Institute of the Brain, Russia |
| ClinicalTrials.gov Identifier: | NCT00901381 History of Changes |
| Other Study ID Numbers: | GKSF-8 |
| Study First Received: | May 12, 2009 |
| Last Updated: | January 6, 2014 |
| Health Authority: | Russia: Ministry of Health of the Russian Federation |
Keywords provided by Clinical Institute of the Brain, Russia:
|
Ischemic stroke Stem cells Colony-stimulating factors Filgrastim Randomized controlled trial |
Additional relevant MeSH terms:
|
Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases |
Vascular Diseases Lenograstim Adjuvants, Immunologic Immunologic Factors Pharmacologic Actions Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on March 03, 2015